02/19/2026
Rep. August Pfluger is calling for stronger oversight of Pharmacy Benefit Managers - and that’s an important step in the conversation around prescription drug costs.
Under recent reforms in the Consolidated Appropriations Act of 2026, PBMs in Medicare Part D must provide expanded reporting on rebates, fees, and how they are compensated. Rep. Pfluger has voiced support for limiting rebate retention and pushing for full pass-through of rebates to health plans.
Why does this matter to patients?
When pricing systems operate without clear transparency, it’s harder to see where savings are going - and easier for costs to rise without explanation. Stronger oversight can help ensure that savings actually reach patients instead of getting absorbed in intermediary systems.
For community pharmacies, this could also mean fairer reimbursement and a more balanced system that protects local access to care.
Transparency is not about politics. It’s about accountability.
Senator Katie Boyd Britt Senator Tommy Tuberville Rep. Terri Sewell Congressman Gary Palmer U.S. Representative Barry Moore Rep. Shomari Figures Congressman Mike D. Rogers Robert Aderholt Representative Dale Strong Pharmacists United for Truth and Transparency National Community Pharmacists Association